Vaccibody receives grant to develop VB10.16

Vaccibody has received a EUR 2 million grant from the Norwegian Research Council's BIA programme to develop a novel therapeutic vaccine against precancerous lesions of the cervix. The new vaccine, VB10.16, will be based on the company's Vaccibody DNA vaccine platform, which targets antigen-presenting cells. Combined with previous funding of EUR 875,000, this new grant will enable the company to take VB10.16 through to clinical trials in early 2014.

Vaccibody receives grant to develop VB10.16

Vaccibody has received a EUR 2 million grant from the Norwegian Research Council's BIA programme to develop a novel therapeutic vaccine against precancerous lesions of the cervix. The new vaccine, VB10.16, will be based on the company's Vaccibody DNA vaccine platform, which targets antigen-presenting cells. Combined with previous funding of EUR 875,000, this new grant will enable the company to take VB10.16 through to clinical trials in early 2014.

×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

×

REQUEST A DEMO

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

A member of the team will be in touch shortly to arrange a convenient time for your free demonstration and trial. If your enquiry is urgent, please email our Client Services team here.